Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash Flows from Operating Activities:
Net Income (loss)	$ (21,945)	$ 12,376
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	647	734
Loss on extinguishment of debt	27,479	0
(Gain)/Loss from change in fair value of hybrid financial instruments	(11,958)	(4,203)
(Gain)/Loss from change in fair value of derivative liability - warrants	(5,818)	(2,263)
(Gain)/Loss from change in fair value of derivative liability - Series C and D preferred stock and debentures	13,262	(12,457)
Interest expense related to convertible debt	4,407	2,812
Interest paid on convertible debt	0	(1,000)
Stock-based compensation expense	15	58
Increase/(decrease) in value of life insurance policies	(527)	133
Changes in operating assets and liabilities
Trade and other accounts receivable	107	(8)
Inventories	0	(35)
Prepaid expenses and other assets	(26)	(84)
Accounts payable and accrued liabilities	811	17
Derecognition of accrued purchase price guarantee and accruals	(8,300)	0
Deferred revenue and other current liabilities	469	409
Net cash used in operating activities	(1,377)	(3,511)
Cash Flows from Investing Activities:
Acquisition of property and equipment	(5)	(6)
Net cash used in investing activities	(5)	(6)
Cash Flows from Financing Activities:
Borrowings under short-term notes payable, net	110	0
Borrowings under convertible debt instruments, net	2,500	3,685
Net cash provided by financing activities	2,610	3,685
Effect of exchange rate changes on cash	18	2
Net change in cash and cash equivalents	1,246	170
Cash and cash equivalents, beginning of period	30	80
Cash and cash equivalents, end of period	1,276	250
Supplemental cash flow information:
Interest paid during the period	0	1,000
Series C preferred stock converted to common stock	878	9,320
Series D preferred stock converted to common stock	2,342	279
Deemed dividend on Series D preferred stock issued	0	3,212
Convertible debentures converted to common stock	13,825	0
Shares issued for acquisition of patent rights	$ 0	$ 350